CADL vs ZTS · $592.0M cap vs P/E 25, rev $2.47B
Candel Therapeutics Inc (CADL) versus Zoetis Inc (ZTS) — a side-by-side from cached financials, not a winner call.
Candel Therapeutics Inc (CADL) is a biotechnology company listed on NASDAQ.
Zoetis Inc (ZTS) is a drug manufacturers - specialty & generic company listed on US.
CADL does not have a complete income-statement cache yet.
Latest reported ZTS revenue for 2026-06-30 was $2.47B. Net income was $691.0M. Revenue was up 9.1% from 2026-03-31 to 2026-06-30. ZTS currently screens at market cap $64.65B and trailing P/E 24.9.
CADL currently screens at market cap $592.0M. ZTS currently screens at market cap $64.65B and trailing P/E 24.9.
Not investment advice. Open the CADL and ZTS stock pages for the full models.
Not investment advice.